Special poster reception on October 13, 2019, at C
Post# of 36533
(Total Views: 233)
Posted On: 10/10/2019 9:19:14 AM
Re: franksullivan #7043
Special poster reception on October 13, 2019, at Caesars Palace, Las Vegas, the official site of the SAWC Meeting
Clinical data demonstrate accelerated healing of diabetic neuropathic foot ulcers with Excellagen wound conforming gel matrix
MIRAMAR, Fla., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation(GNBT) is pleased and proud to announce that Dr. Lois Chandler, inventor of Excellagen and an advisor to our subsidiary, Olaregen Therapeutix, will be presenting the poster entitled “Wound Conforming Matrix Containing Purified Homogenate of Dermal Collagen Promotes Rapid Healing of Diabetic Neuropathic Foot Ulcers: Subset Analysis of Randomized Controlled Trial” during a special poster reception on October 13, 2019, at Caesars Palace, Las Vegas, the official site of the SAWC Meeting. The poster will present clinical data demonstrating significant acceleration of healing rates in patients with chronic diabetic neuropathic foot ulcers following a single application of Olaregen’s Excellagen (2.6% formulated fibrillar collagen) and increased wound closure incidences as compared with Standard of Care (SOC).
Dr. Chandler’s co-authors on the poster include Oscar Alvarez, PhD of Rutgers University, Peter Blume, DPM, FACFAS of Yale University, Paul Kim, DPM of the University of Texas, Robert Kirsner, MD, PhD of the University of Miami, John Lantis, MD of Mount Sinai Hospital – NY, and William Marston, MD of the University of North Carolina.
“We are excited for Dr. Chandler to present the clinical trial data that demonstrates statistically significant healing rates in diabetic foot ulcers with just a single application of Excellagen.” said Anthony J. Dolisi, President and Chief Executive Officer of Olaregen and Chief Commercial Officer for Generex. “We are happy to report that we continue to see these results replicated in clinical practice as we launch Excellagen in three sizes including 0.5, 0.8, and now 3.0 cc pre-filled syringes.”
Clinical data demonstrate accelerated healing of diabetic neuropathic foot ulcers with Excellagen wound conforming gel matrix
MIRAMAR, Fla., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation(GNBT) is pleased and proud to announce that Dr. Lois Chandler, inventor of Excellagen and an advisor to our subsidiary, Olaregen Therapeutix, will be presenting the poster entitled “Wound Conforming Matrix Containing Purified Homogenate of Dermal Collagen Promotes Rapid Healing of Diabetic Neuropathic Foot Ulcers: Subset Analysis of Randomized Controlled Trial” during a special poster reception on October 13, 2019, at Caesars Palace, Las Vegas, the official site of the SAWC Meeting. The poster will present clinical data demonstrating significant acceleration of healing rates in patients with chronic diabetic neuropathic foot ulcers following a single application of Olaregen’s Excellagen (2.6% formulated fibrillar collagen) and increased wound closure incidences as compared with Standard of Care (SOC).
Dr. Chandler’s co-authors on the poster include Oscar Alvarez, PhD of Rutgers University, Peter Blume, DPM, FACFAS of Yale University, Paul Kim, DPM of the University of Texas, Robert Kirsner, MD, PhD of the University of Miami, John Lantis, MD of Mount Sinai Hospital – NY, and William Marston, MD of the University of North Carolina.
“We are excited for Dr. Chandler to present the clinical trial data that demonstrates statistically significant healing rates in diabetic foot ulcers with just a single application of Excellagen.” said Anthony J. Dolisi, President and Chief Executive Officer of Olaregen and Chief Commercial Officer for Generex. “We are happy to report that we continue to see these results replicated in clinical practice as we launch Excellagen in three sizes including 0.5, 0.8, and now 3.0 cc pre-filled syringes.”
(2)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼